Press Releases

Date Title and Summary  
Toggle Summary Geron Announces New Overall Survival Data from IMbark in Imetelstat-Treated Patients with Intermediate-2 or High-Risk Myelofibrosis and Relapsed/Refractory to Janus Kinase Inhibitor Therapy
Data Reporting Median Overall Survival of 29.9 Months in High-Dose Arm Presented at the 60th American Society of Hematology Annual Meeting MENLO PARK, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that results from IMbark, a Phase 2 clinical trial of
Toggle Summary Geron Reports Updated Results from Phase 2 Portion of IMerge at the 60th American Society of Hematology Annual Meeting
Data Support Initiation of Part 2, the Phase 3 portion of IMerge MENLO PARK, Calif. , Dec. 03, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that updated results from Part 1 of IMerge, the Phase 2 portion of a Phase 2/3 clinical trial of imetelstat in lower risk
Toggle Summary Geron to Host Analyst and Investor Event on December 10, 2018
MENLO PARK, Calif. , Nov. 28, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that the Company’s analyst and investor event will take place in New York, N.Y. , on Monday, December 10, 2018 . Management will be joined by clinical investigators from both IMerge and IMbark
Toggle Summary Geron to Present at Upcoming Investor Conferences in November
MENLO PARK, Calif. , Nov. 07, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that John A. Scarlett , M.D., President and Chief Executive Officer, is scheduled to present a company overview at the following investor conferences: Stifel 2018 Healthcare Conference in New
Toggle Summary Geron Corporation Reports Third Quarter 2018 Financial Results and Recent Company Events
Imetelstat program transition proceeding, including plans to initiate Phase 3 portion of IMerge Abstracts for IMbark and IMerge accepted for oral presentation at American Society of Hematology Meeting (ASH) in December Conference call scheduled for 4:30 p.m. ET today MENLO PARK, Calif. , Nov.
Toggle Summary Geron Announces Two Oral Presentations on Imetelstat at Upcoming American Society of Hematology Annual Meeting
Clinical Data from Part 1 of IMerge in Myelodysplastic Syndromes and IMbark Primary Analysis in Myelofibrosis to be Presented MENLO PARK, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) --   Geron Corporation (Nasdaq: GERN) today announced that clinical data related to imetelstat, the Company’s
Toggle Summary Geron to Announce Third Quarter 2018 Financial Results on November 1, 2018
MENLO PARK, Calif. , Oct. 25, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will release its third quarter 2018 financial results after the market closes on Thursday, November 1, 2018 . The financial press release will be available on the Company’s website at
Toggle Summary Geron Announces Discontinuation of Imetelstat Collaboration by Janssen
Geron regains global rights to imetelstat program Highlights reported for IMerge and IMbark Geron plans to initiate the Phase 3 portion of IMerge Conference call scheduled for 8:00 a.m. ET today MENLO PARK, Calif. , Sept. 27, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced
Toggle Summary Geron to Provide an Update on the Imetelstat Collaboration with Janssen on September 27, 2018
MENLO PARK, Calif. , Sept. 26, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today announced that it will host a conference call to provide an update on the imetelstat collaboration with Janssen Biotech, Inc. (Janssen) on Thursday, September 27th at 8:00 a.m. ET .
Toggle Summary Geron Corporation Reports Second Quarter 2018 Financial Results and Recent Company Events
Conference Call Scheduled for July 31 at 4:30 p.m. ET MENLO PARK, Calif. , July 31, 2018 (GLOBE NEWSWIRE) -- Geron Corporation (Nasdaq: GERN) today reported financial results for the three and six months ended June 30, 2018 . Second Quarter and Year to Date 2018 Results For the second quarter of